|
The preface, table of contents and abstract, of the Draft Hazard
Identification Document for Benzeze are available for on-screen
viewing. The full text of the Hazard Identification Document may
be downloaded as a 928 Kb Adobe Acrobat .pdf file.
go
to the download area
PREFACE
The Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition
65, California Health and Safety Code 25249.5 et seq.) requires
that the Governor cause to be published a list of those chemicals
"known to the state" to cause cancer or reproductive toxicity.
The Act specifies that "a chemical is known to the state to
cause cancer or reproductive toxicity if in the opinion of the states
qualified experts the chemical has been clearly shown through scientifically
valid testing according to generally accepted principals to cause
cancer or reproductive toxicity." The lead agency for implementing
Proposition 65 is the Office of Environmental Health Hazard Assessment
of the California Environmental Protection Agency. The "states
qualified experts" regarding findings of reproductive toxicity
are identified as members of the Developmental and Reproductive
Toxicant Identification Committee of the Office of Environmental
Health Hazard Assessments Science Advisory Board (22 CCR 12301).
During a public meeting held in Sacramento, California, on May
12, 1995 the Committee selected benzene as a candidate for evaluation
and requested that OEHHA staff prepare a review of the scientific
evidence relevant to the reproductive toxicity of this agent. This
draft document, which was released to the Committee and the public
on September 5, 1997, responds to that request. While this hazard
identification document does not provide dose-response evaluation,
exposure assessment, or determination of allowable or safe exposure
levels, the document does provide information which may be useful
in such appraisals.
A public meeting of the Committee will be held December 9, 1997,
in Sacramento, California. Following discussion and Committee deliberation,
the Committee may determine whether or not benzene "has been
clearly shown through scientifically valid testing according to
generally accepted principles" to cause reproductive toxicity
or may defer action.
|
TABLE OF CONTENTS
|
| PREFACE |
2 |
| A. Abstract |
5 |
| B. Introduction |
7 |
| B.1. Chemical structure and main physical
characteristics |
7 |
| B.2. Regulatory history |
7 |
| B.3. Exposure information |
7 |
| B.4. Pharmacokinetics |
9 |
| B.4.1. Absorption |
9 |
| B.4.2. Distribution |
10 |
| B.4.3. Metabolism |
11 |
| B.4.4. Elimination and excretion |
14 |
| B.5. Non-DART toxicities |
15 |
| B.5.1. Human non-DART toxicities |
15 |
| B.5.2. Experimental animal non-DART toxicities |
16 |
| B.5.3. Benzene metabolites and non-DART toxicities |
21 |
| C. Developmental Toxicity |
22 |
| C.1. Human developmental toxicity studies. |
22 |
| C.1.1. Fetal growth |
23 |
| C.1.2. Spontaneous abortion and perinatal
mortality |
25 |
| C.1.3. Birth defects |
28 |
| C.1.4. Childhood leukemia |
30 |
| C.2. Animal developmental toxicity studies |
31 |
| C.2.1. Inhalation exposure during embryonic
development: fetal growth retardation |
31 |
| Rats |
31 |
| Mice |
32 |
| Rabbits |
33 |
| Maternal toxicity |
33 |
| C.2.2. Inhalation exposure during embryonic
development: gross, soft tissue and skeletal findings |
34 |
| C.2.3. Oral administration during embryonic
development |
35 |
| C.2.4. Injection during embryonic development |
35 |
| C.2.5. Interaction of benzene with other agents
during embryonic development |
36 |
| C.2.6. Transplacental genotoxicity and carcinogenicity |
36 |
| C.2.7. Transplacental hematopoietic toxicity |
37 |
| C.3. Developmental toxicity: Other relevant
data |
41 |
| C.3.1. Distribution and metabolism in pregnant
females and conceptuses |
41 |
| C.3.2. Mechanism(s) of benzene developmental
toxicity |
45 |
| C.3.2.1. Active agent |
45 |
| C.3.2.2. Biological mechanisms of action |
47 |
| C.4. Integrative evaluation |
47 |
| D. Female Reproductive Toxicity |
54 |
| D.1. Human female reproductive toxicity studies |
54 |
| D.2. Animal female reproductive toxicity studies |
56 |
| D.2.1. Fertility |
56 |
| D.2.2. Reproductive organ toxicity |
57 |
| D.3. Female reproductive toxicity: Other relevant
data |
58 |
| D.3.1. Distribution and metabolism in females |
58 |
| D.3.2. Chromosomal aberrations and related
effects of benzene metabolites |
58 |
| D.3.3. Effect of benzene on noradrenergic
nerves of ovaries and uterus |
59 |
| D.4. Integrative evaluation |
64 |
| E. Male Reproductive Toxicity |
64 |
| E.1. Human male reproductive toxicity studies |
64 |
| E.1.1. Fetal growth |
64 |
| E.1.2. Spontaneous abortion and perinatal
mortality |
65 |
| E.1.3. Childhood leukemia |
67 |
| E.2. Animal male reproductive toxicity studies |
68 |
| E.2.1. Effects on sperm |
69 |
| E.2.2. Fertility/dominant lethal |
69 |
| E.2.3. Reproductive organ pathology |
70 |
| E.3. Male reproductive toxicity: Other relevant
data |
71 |
| E.3.1. Distribution and metabolism in males |
71 |
| E.3.2. Chromosomal aberrations and related
effects of benzene metabolites |
71 |
| E.4. Integrative evaluation |
72 |
| F. Summary |
77 |
| F.1. Developmental Toxicity |
77 |
| F.2. Female Reproductive Toxicity |
77 |
| F.3. Male Reproductive Toxicity |
77 |
| G. References |
78 |
Abstract
Exposures to benzene occur in connection with auto exhaust, auto
fueling, tobacco smoke, and, in occupational settings, through its
use as a chemical intermediate and as a component of petroleum products.
Known toxic effects of benzene in humans include induction of myeloid
leukemia and aplastic anemia. Benzene metabolites are clastogenic
and target hematopoietic precursor cells.
There are a number of studies of the consequences of benzene exposure
during organogenesis in mice, rats and rabbits, many of which used
the inhalation route, which is the most common route of exposure
for humans. The animal studies have consistently found developmental
retardation as reflected in fetal weight and skeletal ossification
at term. These effects occurred in the absence of reported maternal
toxicity at some benzene concentrations. In mice, benzene also caused
clastogenic effects and altered populations of hematopoietic precursors
in the fetus when administered to the dam.
Relevant human studies have examined pregnancy outcome in relation
to maternal occupational exposure to benzene, usually as one of
a number of organic solvents, or environmental exposure to benzene
as one of a number of contaminants. In case-control studies investigating
maternal exposure to benzene as one of a number of concurrent exposures,
there were elevated odds ratios, though most were not statistically
significant, associated with adverse effects on fetal growth (preterm
delivery), fetal loss (stillbirth), and birth defects (neural tube
and major cardiac defects), as well as childhood leukemia. More
definitive studies with assessment of benzene-specific exposure
are needed to evaluate the suggested associations.
Female reproductive toxicity was not reported in the few relevant
studies in the animal literature. However, in human studies, consistent
reports of abnormal menstruation and excessive blood loss during
childbirth in women occupationally exposed to benzene have been
identified in 3 cross-sectional studies and in case series and case
reports. More definitive studies with accurate assessment of benzene-specific
exposure are needed to further evaluate the associations suggested
by these studies.
Male reproductive toxicity studies in animals have reported benzene-induced
damage to testes and sperm, including chromosomal damage. Dominant
lethal effects were not reported in available rat and mouse studies.
In humans, associations have been reported between paternal occupational
benzene exposure and both fetal growth effects and fetal loss; a
case-control study reported statistically significant elevated risks
of small-for-gestational-age infants and stillbirth, while a cohort
study found nonsignificant elevated risks of spontaneous abortion.
Of 2 case-control studies of paternal benzene exposure and risk
of childhood leukemia and non-Hodgkins lymphoma, the more
recent study with better exposure assessment reported a statistically
significant association while the earlier one failed to find such
an association. Studies with accurate assessment of benzene-specific
exposure are needed to evaluate the association between pre-conceptional
paternal exposure to benzene and childhood leukemia.
Biological plausibility for some benzene developmental and male
reproductive effects can be inferred from benzene effects on chromosomes
and hematopoietic cells. There has been no direct inquiry into the
mechanism of delayed intrauterine development effects. The data
appear consistent with both direct effects of benzene and with effects
of benzene metabolites.
Download
the entire Benzene
Hazard Identification Document as an Adobe Acrobat pdf file
You will need the free program Adobe Acrobat Reader to view or
print PDF files 
For questions regarding Proposition 65, please contact the Cynthia
Oshita in the Proposition 65 Implementation Program
For help with this web site please contact the Web
Mistress
|